A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY® Study)
Latest Information Update: 08 Apr 2025
At a glance
- Drugs BI 1291583 (Primary)
- Indications Bronchiectasis
- Focus Registrational; Therapeutic Use
- Acronyms The AIRTIVITY Study
- Sponsors Boehringer Ingelheim
- 18 Mar 2025 New trial record